# A Single-arm Phase 2 Prospective Clinical Study of Enatumab in the Treatment of Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia

> **NCT07190261** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Bing Han** · enrollment: 3 (estimated)

## Conditions studied

- Autoimmune Hemolytic Anemia

## Interventions

- **DRUG:** enatumab

## Key facts

- **NCT ID:** NCT07190261
- **Lead sponsor:** Bing Han
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-18
- **Primary completion:** 2027-09-18
- **Final completion:** 2027-09-18
- **Target enrollment:** 3 (ESTIMATED)
- **Last updated:** 2025-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07190261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07190261, "A Single-arm Phase 2 Prospective Clinical Study of Enatumab in the Treatment of Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07190261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*